HK1141447A1 - Pharmaceutical composition for the treatment of proliferative diseases - Google Patents
Pharmaceutical composition for the treatment of proliferative diseasesInfo
- Publication number
- HK1141447A1 HK1141447A1 HK10107872.6A HK10107872A HK1141447A1 HK 1141447 A1 HK1141447 A1 HK 1141447A1 HK 10107872 A HK10107872 A HK 10107872A HK 1141447 A1 HK1141447 A1 HK 1141447A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- pharmaceutical composition
- proliferative diseases
- proliferative
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101496507A CN101675930B (en) | 2008-09-16 | 2008-09-16 | Pharmaceutical composition for treating hyperplasia diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1141447A1 true HK1141447A1 (en) | 2010-11-12 |
Family
ID=42028743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10107872.6A HK1141447A1 (en) | 2008-09-16 | 2010-08-18 | Pharmaceutical composition for the treatment of proliferative diseases |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN101675930B (en) |
HK (1) | HK1141447A1 (en) |
WO (1) | WO2010031265A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102271848B1 (en) * | 2013-11-01 | 2021-07-01 | 피트니 파마슈티컬스 피티와이 리미티드 | Pharmaceutical combinations for the treatment of cancer |
CN104086484B (en) * | 2014-07-08 | 2016-05-25 | 上海宣创生物科技有限公司 | Mesylate solvate crystal of nicotinamide derivative and its preparation method and application |
CN104072412A (en) * | 2014-07-08 | 2014-10-01 | 上海宣创生物科技有限公司 | Mesylate B crystal form of nicotinamide derivative, preparation method and application of mesylate B crystal form |
CN105541708A (en) * | 2014-10-28 | 2016-05-04 | 华东理工常熟研究院有限公司 | New crystal form of apatinib sulfate |
CN105622499A (en) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | New crystal of apatinib sulfate |
CN105622498A (en) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | New crystal of apatinib sulfate |
CN106176757B (en) * | 2015-05-25 | 2019-12-10 | 江苏恒瑞医药股份有限公司 | application of combination of compound and tegafur in preparation of medicine for treating proliferative diseases |
CN107669685A (en) * | 2016-08-02 | 2018-02-09 | 江苏恒瑞医药股份有限公司 | A Pa combines for preparing the purposes in the medicine for treating stomach cancer for Buddhist nun with Tegafur and Taxane family |
TWI764943B (en) | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | Combination use of anti-pd-1 antibody and vegfr inhibitor in the preparation of a medicament for the treatment of cancer |
JP2021508699A (en) | 2017-12-29 | 2021-03-11 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Use of combined treatment with PD-1 antibody and apatinib to treat triple-negative breast cancer |
CN108409647B (en) * | 2018-03-14 | 2020-03-24 | 盐城师范学院 | Preparation method of apatinib |
CN108524938B (en) * | 2018-06-15 | 2020-06-19 | 深圳大学 | Application of CDK6 small-molecule inhibitor in reducing tolerance of liver cancer cells to antitumor drugs or radiotherapy |
CN110841607B (en) * | 2019-11-22 | 2020-07-24 | 中国科学院地质与地球物理研究所 | Ultra-low-cost priming gold special-effect resin and preparation and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1281590C (en) * | 2002-11-27 | 2006-10-25 | 南京凯衡科贸有限公司 | Hexavalent amino amidate derivative with function of inhibiting blood vessel growth activity |
-
2008
- 2008-09-16 CN CN2008101496507A patent/CN101675930B/en active Active
-
2009
- 2009-06-11 WO PCT/CN2009/072238 patent/WO2010031265A1/en active Application Filing
-
2010
- 2010-08-18 HK HK10107872.6A patent/HK1141447A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2010031265A1 (en) | 2010-03-25 |
CN101675930A (en) | 2010-03-24 |
CN101675930B (en) | 2012-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL200862A0 (en) | 3-imidazolyl-indoles for the treatment of proliferative diseases | |
HK1141447A1 (en) | Pharmaceutical composition for the treatment of proliferative diseases | |
SI2001892T1 (en) | Imidazolothiazole compounds for the treatment of proliferative diseases | |
HK1163500A1 (en) | Pharmaceutical composition for the treatment of heart diseases | |
HK1154575A1 (en) | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | |
IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
LT2303330T (en) | Pharmaceutical compositions for treatment of parkinson`s disease | |
EP2291157A4 (en) | Compositions and methods for the transdermal delivery of pharmaceutical compounds | |
IL207546A0 (en) | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases | |
IL208357A0 (en) | Spiro-indole derivatives for the treatment of parasitic diseases | |
PT2358373E (en) | Injectable polydeoxyribonucleotide composition for the treatment of osteoarticular diseases | |
GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
EP2213303A4 (en) | Pharmaceutical composition for treatment of cataract | |
ZA201009072B (en) | Pharmaceutical composition for the treatment of premature ejaculation | |
GB0715790D0 (en) | Drug combination for the treatment of sialorrhoea | |
HK1155659A1 (en) | Pharmaceutical composition for treatment of fibromyalgia | |
PL2604264T3 (en) | Pharmaceutical composition for treating viral diseases | |
EP2142566A4 (en) | Methods and compositions for the treatment of proliferative diseases | |
PL385972A1 (en) | Pharmaceutical composition for therapy of parodonthium deseases | |
IL200753A (en) | Pharmaceutical composition comprising ib-meca for the treatment of psoriasis | |
ZA201204341B (en) | Pharmaceutical composition for treating gutaneous burns | |
EP2402342A4 (en) | Pharmaceutical composition for treatment of 2 type diabetes | |
PL2344166T3 (en) | Pharmaceutical composition for the treatment of gastrointestinal irritation disorders | |
EP2467492A4 (en) | Methods and compositions for the treatment of proliferative and pathogenic diseases | |
EP2329824A4 (en) | Novel pharmaceutical composition for treatment of nociceptive pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220911 |